Diabetology International, published by Springer Japan KK, is a leading journal dedicated to the field of diabetes research. With an ISSN of 2190-1678 and E-ISSN of 2190-1686, this journal plays a pivotal role in disseminating innovative studies and findings that advance understanding in endocrinology, diabetes, and metabolism. Its rigorous peer-review process ensures the publication of high-quality research articles, review papers, and clinical studies, making it a valuable resource for researchers, healthcare professionals, and students. The journal is indexed in Scopus and maintains respectable rankings in its categories, standing at Q3 in Endocrinology, Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. Furthermore, the journal facilitates collaborations and promotes the exchange of ideas from its base in Tokyo, Japan, helping to bridge the gap between academia and clinical practice. As it converges through the years from 2010 to 2024, Diabetology International remains committed to addressing the evolving challenges in diabetes care and research, supporting the global community's pursuit of knowledge in this crucial field.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

The Journal of Diabetology, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 2010, this Open Access journal has provided researchers and healthcare professionals with a wealth of knowledge through rigorous peer-reviewed articles that cover clinical research, epidemiology, and innovative treatment strategies. With an E-ISSN of 2078-7685 and a commitment to disseminating high-quality scientific work, the journal plays a pivotal role in contributing to the global discourse on diabetes care and prevention. Its dedication to accessibility enhances its impact on both established scholars and emerging researchers seeking to make meaningful contributions in the field. By fostering a collaborative environment, the Journal of Diabetology aims to bridge the gap between research and practical implementation, ultimately improving outcomes for individuals affected by diabetes.

DIABETIC MEDICINE is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of endocrinology, specifically focusing on the pathophysiology, management, and prevention of diabetes mellitus and its complications. With an impressive impact factor reflecting its significant role in shaping clinical practice and research, DIABETIC MEDICINE holds a prominent position among its peers, categorized in the Q1 quartiles for Endocrinology, Diabetes and Metabolism, and Internal Medicine. Since its inception in 1984, the journal has provided a platform for rigorous and innovative research, fostering collaborative efforts among researchers, clinicians, and students to enhance diabetes care. The journal is esteemed for its high-ranking performance in Scopus, highlighted by its ranking of #33 in Internal Medicine and #64 in Endocrinology, Diabetes, and Metabolism. By offering insightful access to groundbreaking studies and reviews, DIABETIC MEDICINE plays a crucial role in informing policy and improving medical outcomes for individuals with diabetes, making it an essential resource for those in medical and clinical research fields.

Diabetes Epidemiology and Management, published by Elsevier, is an innovative open-access journal that has been addressing the critical issues surrounding diabetes since its inception in 2021. This journal integrates a comprehensive exploration of the epidemiology, prevention, and management of diabetes, making it a pivotal resource within the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine. With a digital presence represented by E-ISSN 2666-9706, it currently holds a commendable position in the academic landscape, categorized in the Q3 quartile for both Endocrinology and Internal Medicine as per the 2023 metrics. The journal aims to enhance understanding and promote research on diabetes, offering authors a platform to share their findings with a global audience. Researchers, professionals, and students alike can benefit from this essential resource, which is dedicated to advancing the knowledge base and improving clinical practices in diabetes management. With open access options since 2021, the journal ensures that vital research is widely accessible, driving innovation and collaboration in the fight against diabetes.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

Journal of Diabetes Research, published by HINDAWI LTD, is a leading open-access journal dedicated to advancing the understanding and management of diabetes. Established in 2013, the journal has swiftly gained recognition, achieving a commendable Q2 ranking in both the categories of Endocrinology and Diabetes and Metabolism, as well as in Biochemistry, Genetics and Molecular Biology. With an impressive Scopus ranking of #42 out of 244 in its field, the journal provides a platform for cutting-edge research that addresses the multifaceted challenges posed by diabetes. Offering unrestricted access to its articles since its inception, the journal aims to foster collaboration and exchange of innovative ideas among researchers, clinicians, and students worldwide. It is particularly vital for those engaged in diabetes research, as it publishes influential studies that impact clinical practices and enhance patient outcomes. For academics and professionals seeking to contribute to the growing body of knowledge in diabetes, the Journal of Diabetes Research serves as a valuable resource.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

DIABETES-METABOLISM RESEARCH AND REVIEWS, published by WILEY, is an esteemed academic journal focusing on the forefront of research in the fields of endocrinology, diabetes, and metabolism. Since its inception in 1999, this journal has become a crucial resource for researchers, professionals, and students, boasting an impressive impact factor that reflects its high citation rates and contribution to the field. With a 2023 classification of Q1 in several categories including Endocrinology and Internal Medicine, it ranks among the top journals globally, demonstrating its significant influence and authority. The journal serves as a platform for the dissemination of innovative research, reviews, and methodologies that advance understanding and treatment of metabolic disorders. By offering valuable insights and fostering collaboration within the scientific community, DIABETES-METABOLISM RESEARCH AND REVIEWS is essential reading for anyone involved in diabetes research and clinical practice.

The Journal of Diabetes and Metabolic Disorders, published by SPRINGER INT PUBL AG, is a premier academic journal dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. With an E-ISSN of 2251-6581, this journal plays a crucial role in disseminating high-quality research findings from 2012 to 2024, serving as a valuable resource for researchers, practitioners, and students alike. Notably, it has achieved impressive rankings, being placed in the Q2 quartile for Internal Medicine and Q3 for Endocrinology, Diabetes, and Metabolism in 2023, reflecting its influence within the scientific community. The Journal’s commitment to open access ensures that its comprehensive articles, encompassing topics from metabolic disorders to novel therapeutic approaches, are readily available to a global audience. Position yourself at the forefront of medical advancements—contribute to and benefit from the pivotal research presented in this journal.